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ESVI ratio (-0.32i1.7 vs. +0.9*2.7 g/cm2 per mUm2, P=O.O3). Within the MVP group, 
those treated with angiotensin-converting enzyme inhibitors (ACE-I, n=50) compared to 
those untreated (n=53) had adjusted for the change rn MR degree, regression of ESVI (- 
0.5*12 vs. +6.4*18 ml/m2, P=O.O2), LVMI (-8228 vs. +3.3&?6, P=O.O2) improvement in 
EF (c2t8 vs. -2+8%, P&02) and decline in ESWS (-11+32 vs. +4+34 g/cm2). 
Conclusion: In patients with organrc MR, LV remodeling development is measurable 
and characterized by increase in LV volume and decrease in LV mass to volume ratio. 
Patients with MVP develop more LV remodeling than those without MVP, particularly 
with measurable decline in LV function. Patients treated by ACE-1 show dissociated 
effects LV remodeling suggesting that the long-term effect of these medications should 
be carefully evaluated. 
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1109MP-163 Echocardiographic Quantification of Annular Dilatation 
and Papillary Muscle Separation in Patients of 
Functional Mitral Regurgitation: Role of Anterior Mitral 
Leaflat Length as Reference 
Vincd Jorapur, Richard Lucariello, New York Medical College, Valhalla, NY 
Background: Management of functtonal mitral regurgitation (FMR) may be optimized by 
quantification of the extent of annular dilatation and papillary muscle separation. We 
hypothesized that anterior mitral leaflet length (ALL) does not ddfer significantly between 
normals and patients with systolic left ventricular dysfunction (LVD) and hence may be 
used es a reference measure to quantify annular dilatation and papillary muscle separa- 
tion. 
Method: 50 controls and 30 patients with LVD, of whom 15 had no or mild MR (effective 
regurgitant orifice area - ERO by flow convergence ~0.2) and 15 had moderate or severe 
MR (EROa.2) were prospecttvely studled by echocardiographic measurement of ALL, 
annular diameter (AD), AD/ALL Index. tnterpapillary distance (IPD), IPD/ALL Index, LV 
end diastolic dimension (LVED) and ejectron fraction (EF). 
Results: 
Controls LVD 
ALL 1.89*0. 1.80*0. 
38 29 
AD 1.62*0. 1.99+0. 
27 27 
ADI 0.87+0. 1.13+0. 
ALL 17 23 
IPD 1.49*0. 2.4&O. 
24 56 
IPD/ 0.81+0. 1.42+0. 
ALL 11 39 
LVED 4.29+0. 5.82+0. 
51 73 
LV EF 0.73iO. 0.3+0.0 
09 7 
P LVD No/Mild LVD Moderate/Severe 
MR MR 
0.22 1.84*0.31 1.75*0.29 
<O.OOO 1.99iO.28 
1 
~0.000 1.1+0.24 
<O.OOO 2.02+0.36 2.91*0.3 
<o.ooo 1.15*0.3 1.69AO.28 
<o.ooo 5.37*0.57 6.3eO.59 
<o.ooo 0.34io.05 
1.99*0.24 
1.16iO.22 0.25 
P 
0.43 
0.5 
co.ooo 
1 
co.ooo 
1 
<o.ooo 
0.26iO.05 <o.ooo 
1 
1. No significant difference in ALL among the three groups. 2. Mean AD/ALL Index 1.26 
times and 1.33 times controls in LVD with and without significant MR, respectively. 3. 
Mean IPDIALL Index 1.42 times and 2.1 times controls in LVD with and without signifi- 
cant MR. respectively. 
Conclusion: 1. ALL can be used es a reference measurement to quantify annular dilata- 
tion and papillary muscle separation in patients of FMR. 2. Stgnificant FMR is associated 
with greater extent of papillary muscle separation than annular dilatation. 3. Extent of 
papillary muscle separation, but not of annular dilatation, differs significantly between 
LVD with and without significant FMR. 
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1109MP-164 Development of Left Ventricular Remodeling in Mitral 
Regurgitation: Influence of Etiology and Treatment 
Maurice L. Enriauez-Sarano, Michael Bellamy, Arsene Basmadjlan, David Messika- 
Zeitoun, Maryann Capps, Mayo Clinic, Rochester, MN 
Background: Mitral Regurgitatron (MR) causes left ventricular (LV) remodeling which IS 
a harbinger of LV dysfunction and of poor outcome. How LV remodeling progresses 
remains unknown es sequentral quantitative studies are not available. 
Methods: In 121 patients with organrc MR (age 64*14 years, 69% male) LV remodeling 
was quantified by echocardiography es LV end-diastolic and end-systolic volume indices 
(EDVI, ESVI), ejection fraction (EF). mass index (LVMI) and end-systolic wall stress 
(ESWS) at diagnosis and 574+455 days later The MR effective regurgitant orifice was 
36+22 mm2 
Results: Overall, there was significant development of LV remodeling with EDVI increas- 
ing from 107+24 to 114+31 mUm2 (+7.6*20 ml/m2. P<O.OOl). As no change in LVMI 
were noted, the ratio LVMIIEDVI decreased from 1 .18t0.31 to 1 .l 1+0.28 glmL (change 
0.07eO.33. P=O.O4). However, development of LV remodeling was much greeter tn 
patients with mitral valve prolapse (MVP, n=l03) than in those without MVP (1x18) with 
larger change I” EDVI (+8.7+20 vs. +1.5+19 mUm2, P=O.O3). and in ESVI (+3*16 vs. 
2.2*12 mUm2, P=O.O4). With no difference in LVMI, the ratio LVMI/EDVI declined more 
in MVP (-0.10*0.3? vs. +0.07+0.31 glmL, P=O.O6). Furthermore, unfavorable change in 
LV function was noted in MVP. measured es EF (+0.2+8 vs. +3.3*8, P=O.O3) or ESWS/ 
1109MP-165 Subclinical Aortic Valve Sclerosis Associates With 
Early Atherosclerotic Changes of Carotid Artery 
Tomomi Nishide Yasuko Yamaura, Nozomi Watanabe, Takashi Akasaka, Kiyoshi 
Yoshida. Graduate School of Medicine, Kobe University, Kobe, Japan, Kawasaki Medical 
School, Kurashiki, Japan 
Background: Recent studies suggest that aortic valve sclerosis (AVS) and atherosclero- 
sis share the wmmon pathophygiologic process. However, little is known about the 
association of degenerative changes on the carotid artery and aortic valve in the early 
stages. We examined the relationship between early carotid atherosclerosis and subclin- 
ical AVS in the general populatton. 
Methods: One hundred forty-one healthy adults (aged 24-79. 65 male) in a geographi- 
cally defined area underwent transthoracic echocardiography and carotid ultrasonogra- 
phy. AVS was defined as highly-echogenic irregular thickening on at least one aortic 
valve leaflet. Intimal-medial thickness (IMT) was measured at bilateral common carotid 
arteries and carotid bulbs to assess atherosclerosis. The mean values of the bilateral 
maximum IMT (IMTmax) were calculated. 
Results: No one had clinically significant aortic valve stenosis, regurgitation or carotid 
artery stenosis. AVS was present in 34 subjects (24 %, 20 male). IMTmax was signifi- 
cantly greater in the subjects with AVS (1.31+0.46 vs. 0.84+0.30mm, ~~0.04) after 
adjustment for standard cardiovascular risk factors. IMTmax over 1 .OOmm was related to 
an increased risk of AVS (adjusted odds ratio; 4.6, 95% Confidence Interval; 1.4-14.7). 
Conclusions: Subclinical AVS was associated with early atherosclerotic changes of the 
carotid artery in the general population, suggesting that similar pathogenesis of athero- 
sclerosis contributes to AVS even in the early stages. 
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1109MP-166 The Effect of Losartan Versus Atenolol on Aortic Valve 
Sclerosis: A LIFE Study 
Michael H. Olsen, Kristian Wachtell, Jonathan N. Belle, Kurt Boman. Eva Gerdts, 
Vasilios Papademetriou, Markku S. Nteminen, Jens Rokkedat Bjdrn Dahldf, Richard B. 
Devereux, Glostrup University Hospital, Copenhagen, Denmark, The Weill Medtcal 
College of Cornell University, New York, NY 
Background: We have demonstrated that aortic valve (AV) sclerosis predicts cardiovas- 
cular events independent of traditional risk factors, suggesting AV sclerosis is a marker 
of susceptibility to different atherogenic factors. Because losartan reduced the incidence 
of stroke more than atenolol, we hypothesized that losartan would prevent progressron of 
AV sclerosis es compared to atenolol. Methods: After two weeks of placebo treatment, 
clintcal, laboratory and echocardiographic variables were assessed in 960 hypertensive 
patients with ECG left ventricular (LV) hypertrophy without known AV stenosis, aged 55. 
80 (mean 66+7) years. The patients were included in the LIFE Study and randomized to 
atenolol- or losartan-based regrmes. Echocardiography was performed again after one 
and four years of treatment. AV sclerosis was defined as valve thrckening or calcification. 
Results: At baseline, 388 patients (40.4%) had AV sclerosis and 15 (1.6%) had mild AV 
stenosis. The prevalence of AV sclerosis and mild AV stenosis increased after one year 
of treatment to 52.3% and 2.4% (P<O.OOl) and increased further after four years of treat- 
ment 63.2% and 4.1% (PsO.001). The prevalence of AV sclerosis and AV stenosrs were 
Independent of randomization to losartan or atenolol treatment (year 1: 51.3 vs. 53.4%, 
NS and year 4: 63.6 vs. 62.5%. NS) (year 1: 2.7 vs. 2.1%. NS and year 4: 4.8 vs. 3.2%, 
